Skip to content

Study · Non-randomized trial · n = 11 · 1998

3 results

A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia.

Bessette L, Carette S, Fossel AH, Lew RA

Scandinavian journal of rheumatology1 Jan 1998Cited by 14 (Europe PMC)

PMID9572636 (opens in a new tab)DOI10.1080/030097498440976 (opens in a new tab)PepBankPUB-09572636
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with fibromyalgia, salmon calcitonin did not significantly improve any of eleven outcome measures.

    In plain wordsIn patients with fibromyalgia, calcitonin did not significantly improve the measured outcomes versus saline.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeEleven outcome measures
    Study

    n = 11

    Comparator
    isotonic saline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    100 IU · subcutaneous · four weeksAs given in this study (human).

    Source sentences

    Summary
    None of the 11 outcomes measures (seven analog scales, dolorimetry score, and three SIP scores) showed a significant improvement with sCT.
    1 context sentence
    Summary · context
    Eleven patients who fulfilled the American College of Rheumatology classification criteria for fibromyalgia were studied in a double-blind, crossover trial in which they alternatively received salmon calcitonin (100 IU s.c.) and isotonic saline (1 cc s.c.) for four weeks, with a four weeks wash-out…
  2. 02HumanNon-randomized trialSafety outcome

    In patients with fibromyalgia, nausea occurred in ten patients during salmon calcitonin treatment.

    In plain wordsTen patients with fibromyalgia had nausea during calcitonin treatment.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedNausea
    Study

    n = 11

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 IU · subcutaneous · four weeksAs given in this study (human).

    Measurements

    Patients with nausea
    10 patients
    reported result

    Source sentences

    Summary
    The principal side effect observed with sCT was nausea in ten patients and erythema in four patients.
    1 context sentence
    Summary · context
    Eleven patients who fulfilled the American College of Rheumatology classification criteria for fibromyalgia were studied in a double-blind, crossover trial in which they alternatively received salmon calcitonin (100 IU s.c.) and isotonic saline (1 cc s.c.) for four weeks, with a four weeks wash-out…
  3. 03HumanNon-randomized trialSafety outcome

    In patients with fibromyalgia, erythema occurred in four patients during salmon calcitonin treatment.

    In plain wordsFour patients with fibromyalgia had skin redness during calcitonin treatment.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedErythema
    Study

    n = 11

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    100 IU · subcutaneous · four weeksAs given in this study (human).

    Measurements

    Patients with erythema
    4 patients
    reported result

    Source sentences

    Summary
    The principal side effect observed with sCT was nausea in ten patients and erythema in four patients.
    1 context sentence
    Summary · context
    Eleven patients who fulfilled the American College of Rheumatology classification criteria for fibromyalgia were studied in a double-blind, crossover trial in which they alternatively received salmon calcitonin (100 IU s.c.) and isotonic saline (1 cc s.c.) for four weeks, with a four weeks wash-out…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

WithdrawnPhase 4NCT00754884

Calcitonin in the Treatment of Fibromyalgia

Unidad de Investigacion en Enfermedades Cronico-Degenerativasn = 0Oct 2008 to Feb 2009

Fibromyalgia

Trial pageClinicalTrials.govUpdated 4 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.